Navigation Links
Arena Pharmaceuticals Announces Public Offering of Common Stock
Date:7/7/2009

SAN DIEGO, July 7, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. will be the sole underwriter for the offering. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on November 25, 2008, which became effective on December 3, 2008. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by telephone at 800.747.3924.

    Contact:  Jack Lief
              President and CEO

              Robert E. Hoffman
              VP, Finance and CFO
              Arena Pharmaceuticals, Inc.
              858.453.7200, ext. 222

www.arenapharm.com


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
2. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
3. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
4. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
5. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
6. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
7. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
8. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
11. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... , ... June 23, 2017 , ... Ulster University, Magee ... 2017 from 9 am to 3 pm to present to graduate students exciting new ... is an original curriculum project led by The Health Improvement Service of the Western ...
(Date:6/23/2017)... The Woodlands, TX (PRWEB) , ... June 23, ... ... provides families and business owners in the Houston area with access to asset ... Foundation for a regional charity event aimed at improving the lives of children ...
(Date:6/22/2017)... ... 2017 , ... Children’s National Health System has ... launch a Rheumatic Heart Disease Center, with the goal of developing innovative strategies ... (RHD) in high-risk, financially disadvantaged countries and low-income communities across the United States. ...
(Date:6/22/2017)... California (PRWEB) , ... June 23, 2017 , ... ... forces in the fight against hunger on June 21, 2017, at the Emeryville ... fight food insecurity and malnutrition around the world. , Rise Against Hunger (formerly ...
(Date:6/20/2017)... ... 20, 2017 , ... Caduceus International Publishing (CIP), a leading ... new online course entitled Personal & Community Health for the Fall ... achieving optimal well-being and teaches students how to apply them in their everyday ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 2017  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, ... Iowa location. The ... features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) ... level of pollutants. "Our new ... better serve our Iowa patients," said ...
(Date:6/2/2017)...  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company ... demonstrating positive biochemical outcomes related to more frequent hemodialysis ... will be presented at the ERA-EDTA Congress being held ... . The research was conducted by ... Europe (KIHDNEy) Cohort team ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: